Allarity Therapeutics, Inc. 8-K

What Happened
Allarity Therapeutics, Inc. announced on February 18, 2026 that the first patients have been dosed with stenoparib and temozolomide in a VA‑funded, investigator‑initiated Phase 2 trial for the treatment of relapsed small cell lung cancer (SCLC). The company filed a press release about the milestone as Exhibit 99.1 to its Form 8‑K dated February 19, 2026.

Key Details

• Date announced: February 18, 2026 (press release filed as Exhibit 99.1 to the 8‑K on Feb 19, 2026).
• Trial type: VA‑funded, investigator‑initiated Phase 2 clinical trial.
• Drugs being tested: stenoparib (Allarity’s candidate) in combination with temozolomide.
• Indication: relapsed small cell lung cancer; first patient dosing confirmed.

Why It Matters
First‑patient dosing is a clear operational milestone that confirms the Phase 2 trial is underway. For investors, this advances Allarity’s clinical development timeline for stenoparib in SCLC and provides a concrete near‑term progress update to monitor (trial enrollment, safety data, and future readouts). The filing does not disclose financial results or material contracts; it primarily notifies the market that the investigator‑initiated, VA‑funded study has begun.